InStride Health, a Specialty Pediatric Anxiety/OCD Outpatient Treatment Provider, Shares Clinically Meaningful Results in First Annual Outcomes Report
InStride Health, in collaboration with McLean Hospital (#1 ranked psychiatric hospital in the US), continues to expand its proven care model to more states in the Northeast US
BOSTON, MA / ACCESSWIRE / October 5, 2023 / InStride Health, a specialty pediatric anxiety and OCD treatment provider, released its first annual outcomes report. Based on the treatment of over 350 patients, InStride Health demonstrated clinically meaningful results of its coordinated care model. Ninety percent of all program graduates with initial elevated scores at baseline (GAD7 >= 8) experienced a reduction in anxiety within two months of treatment, with an average symptom reduction of 46%. Within just 4 months of starting treatment, the reduction of anxiety symptoms was clinically meaningful for over 80% of patients. Additionally, within 3 months of enrollment, 82% of patients reported reduced functional impairment. Caregivers also saw a positive impact, with 91% reporting a reduction in their own distress and an 86% reduction in work absenteeism within seven months of their child’s treatment initiation. 100% of patients and 97% of caregivers report they would recommend InStride Health to a friend.
Working in collaboration with McLean Hospital – the largest psychiatric affiliate of Harvard Medical School – InStride Health treats all severity levels for anxiety and OCD, with particular focus on those with moderate to severe conditions where anxiety and/or OCD are interfering with functioning and causing a cascade of additional problems (e.g, social isolation, school avoidance, physical manifestations, depression and hopelessness). InStride Health is taking on the broken mental health system by offering easy, insurance-based access to a clinical team with the training, expertise, and treatment approach specifically geared for the needs of pediatric anxiety and OCD.
InStride’s model is based on strong clinical outcomes data and decades of hands-on experience. InStride’s Harvard-trained clinical co-founders, Mona Potter, MD, and Kathryn Boger, PhD, ABPP, co-developed the McLean Anxiety Mastery Program (MAMP), nationally recognized for its evidence-based approach in treating children and adolescents struggling with moderate to severe anxiety and OCD. Its success serves as the foundation for InStride’s care model. Both Drs. Potter and Boger maintain part-time faculty appointments at McLean Hospital, part of Mass General Brigham. McLean is also providing advisory services to continuously improve InStride’s treatment program.
“As a nurse and strong patient advocate who makes referrals worldwide, I wholeheartedly endorse InStride Health. This is a long-awaited, empirically validated treatment program for those seeking highly educated and well-trained professionals to deliver stellar clinical care efficiently, effectively and even accepts most major insurance plans. InStride Health for the win!” said Bonnie Brown, BS, RN, Nurse Administrator and Health Communications Specialist.
InStride patients and their families engage in a tailored outpatient virtual care journey that can include individual and family therapy, groups for kids and for parents, coaching, and medication management (if appropriate), delivered by a highly experienced and coordinated care team of psychiatrists, therapists, and coaches. “Every member of our team understands what a privilege it is to be part of a child and family’s journey,” said John Voith, co-founder and CEO. “We bring heart to our work and ensure we are working smart as we take on our important mission.”
InStride continues to grow throughout the Northeast US. To meet the increasing demand for specialty services, InStride has expanded access to patients and families residing in New York, New Jersey, Connecticut, Massachusetts, New Hampshire, and Rhode Island. Furthermore, InStride Health continues to add new insurance carriers and is now covered by: Anthem Blue Cross Blue Shield of Connecticut, Anthem Blue Cross Blue Shield of New Hampshire, Blue Cross Blue Shield of Massachusetts, ConnectiCare, Harvard Pilgrim, Horizon Blue Cross Blue Shield of New Jersey, Mass General Brigham Health Plan, Optum, Oscar, Oxford, and UnitedHealthcare. More carriers are coming soon.
“Kat (InStride clinical co-founder) and I were very happy in our leadership positions in the academic medical world, until we realized just how great the need was for our treatment beyond our hospital walls,” said Mona Potter, MD, chief medical officer and co-founder of InStride Health. “We built InStride to improve the pediatric mental health system – as moms and clinicians we fully believe we have to fight hard to ensure kids and families get access to care that works – because the right care really changes lives.”
InStride-McLean Collaboration
McLean Hospital, part of Mass General Brigham, is a world-recognized leader in psychiatric care, research, professional and community education, outreach, and advocacy and is providing a range of advisory services to further InStride’s growth. Several McLean leaders serve on Instride’s advisory board.
“InStride’s strategic collaboration with McLean, distinguished by their excellence in clinical care, cutting-edge research, and clinical training, positions us to respond to an urgent need to provide effective and accessible care for children, teens, and young adults ages 7-22 years old with anxiety and OCD, particularly those with moderate to severe conditions,” said John Voith, chief executive officer and co-founder, InStride Health.
“There is power in the InStride-McLean collaboration,” said Scott L. Rauch, MD, president and psychiatrist in chief, McLean Hospital. “During their tenure at McLean, Drs. Potter and Boger demonstrated deep expertise and passion for helping children and families with anxiety. They are leaders in pediatric mental health and we are thrilled to work with them as they expand access to intensive outpatient anxiety and OCD care and achieve their vision.”
XXX
ABOUT INSTRIDE HEALTH
Co-founded by the clinicians who co-developed the McLean Anxiety Mastery Program (MAMP) at McLean Hospital, the nationally recognized program for children and adolescents with moderate to severe anxiety and OCD, InStride Health offers human-first, technology-enhanced specialty mental health treatment. Through their proven coordinated care model, InStride is leading the way to provide insurance-based access to treatment of pediatric anxiety and OCD that actually works. Driven by the belief that children and families living with mental health struggles deserve better, InStride is more than a continuum of care-it’s a pathway to a healthier life and hope for a more promising future. www.instride.health.
ABOUT McLEAN HOSPITAL
McLean Hospital has a continuous commitment to put people first in patient care, innovation and discovery, and shared knowledge related to mental health. It is consistently named the #1 freestanding psychiatric hospital in the United States by U.S. News & World Report. McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of the Mass General Brigham healthcare system. www.mcleanhospital.org.
Contact Information
Alexis Ducharme
Director of Marketing
alexis.ducharme@instride.health
855.438.8331 ext: 751
SOURCE: InStride Health
View source version on accesswire.com:
https://www.accesswire.com/790164/instride-health-a-specialty-pediatric-anxietyocd-outpatient-treatment-provider-shares-clinically-meaningful-results-in-first-annual-outcomes-report
